Virios Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 1, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 1, 2024

DWTX$1.20-6.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 16. Form 10 K Summary

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on March 1, 2024.


	VIRIOS THERAPEUTICS, INC.

	By:	/s/ Greg Duncan
		Greg Duncan
		Chairman of the Board of Directors, and
		Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below on March 1, 2024 by the following persons on behalf of the registrant and in the capacities indicated:


Signature		Title

/s/ Greg Duncan		Chairman of the Board of Directors, and
Greg Duncan		Chief Executive Officer
		(Principal Executive Officer)

/s/ Angela Walsh		Senior Vice President of Finance, Corporate Secretaryand Treasurer
Angela Walsh		(Principal Financial and Accounting Officer)

/s/ Richard Burch		Director
Richard Burch

/s/ Abel De La Rosa		Director
Abel De La Rosa

/s/ David Keefer		Director
David Keefer

/s/ William L. Pridgen, MD		Director
William L. Pridgen, M.D.

/s/ John C. Thomas, Jr.		Director
John C. Thomas, Jr.

/s/ Richard J. Whitley, MD		Director
Richard J. Whitley, M.D.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.